Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Q32 Bio Names Adrien Sipos as Interim CMO to Lead Alopecia Areata Drug Development
Q32 Bio appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to oversee the ongoing SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata treatment.
Biogen Advances Salanersen to Phase 3 Studies for Spinal Muscular Atrophy After Promising Results
Biogen's salanersen (BIIB115/ION306) demonstrated substantial slowing of neurodegeneration and clinically meaningful motor function improvements in children with spinal muscular atrophy previously treated with gene therapy.
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia
Biogen has initiated the BRAVE study, a global Phase 3 clinical trial evaluating omaveloxolone in children aged 2 to 16 years with Friedreich ataxia.
Maxion Therapeutics Strengthens Leadership with Appointment of Dr. Stefan Härtle as Chief Development Officer
Maxion Therapeutics has appointed Dr. Stefan Härtle as Chief Development Officer, bringing nearly 20 years of pharmaceutical R&D experience to advance the company's KnotBody® platform into clinical trials.
Supernus Pharmaceuticals Acquires Sage Therapeutics for $795 Million, Strengthening Neuropsychiatry Portfolio
Supernus Pharmaceuticals announced a definitive agreement to acquire Sage Therapeutics for $8.50 per share upfront plus contingent payments up to $3.50 per share, totaling up to $795 million.
Supernus Pharmaceuticals Acquires Sage Therapeutics for Up to $795 Million, Securing Postpartum Depression Drug Zurzuvae
Supernus Pharmaceuticals agreed to acquire Sage Therapeutics for up to $795 million, offering $8.50 per share in cash plus contingent value rights worth $3.50 per share based on sales milestones.
Comprehensive Analysis Reveals 943 Autoimmune Collaboration and Licensing Deals Across 30 Diseases from 2016-2025
A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.
Candel Therapeutics Strengthens Board with Industry Veteran Ahead of Key BLA Submission
Candel Therapeutics appointed Dr. Maha Radhakrishnan to its Board of Directors, bringing over 20 years of product development and commercialization experience from major biotech and pharmaceutical companies.
Vima Therapeutics Emerges with $60M to Develop First Oral Therapy for Dystonia
Vima Therapeutics launched with $60 million Series A funding led by Atlas Venture to advance VIM0423, a potential first-in-class oral therapy for dystonia targeting muscarinic cholinergic receptors.
Hillstar Bio Strengthens Leadership Team with Key Appointments to Advance Precision Immunotherapy Pipeline
Hillstar Bio appointed Maude Tessier, Ph.D., as Chief Operating Officer and Shiva Krupa, Ph.D., MBA, as Vice President of Program Management to strengthen leadership capabilities.